Search - tctmd.com

Displaying 261 - 280 of 319

Presentation TCT 2012

Outcomes Following Unprotected Left Main Stenting with Everolimus-Eluting Stents: the Milan Experience.

Presenter: Gill L. Buchanan, Alfonso Ielasi, Alaide Chieffo, Matteo Montorfano, Cosmo Godino, Azeem Latib, Mauro Carlino, Antonio Colombo

January 03, 2012

Presentation TCT 2012

Everolimus-eluting stents show no stent thrombosis with similar one year outcomes compared with 1st and 2nd generation drug-eluting stents for the treatment of ST-segment...

Presenter: Kyounghoon Lee, Tae Hoon Ahn, Soon Yong Suh, Woong Chol Kang, Seung Hwan Han, Eak Kyun Shin

January 03, 2012

Presentation TCT 2012

Comparison by Optical Frequency-Domain Imaging of Paclitaxel-Eluting Stents and Everolimus-Eluting Stents Implanted in One Coronary Artery in One Procedure. A 12 Months Follow...

Presenter: Jose M. De la Torre Hernandez, Dae-Hyun Lee, Tamara Garcia Camarero, Piedad Lerena, Gonzalo Martin Gorria, Fermin Sainz Laso, Javier Zueco

January 03, 2012

News Conference News

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

L.A. McKeown

November 28, 2011

News Industry News

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

November 13, 2011

News Industry News

Paclitaxel-coated balloon angioplasty demonstrates superior results

November 10, 2011

News Industry News

Head-to-head comparison of two second generation drug-eluting coronary stents demonstrates non-inferiority

November 10, 2011

News Conference News

EVOLVE: Bioabsorbable EES Noninferior to Permanent Polymer Version

November 10, 2011

News Industry News

Clinical trial establishes non-inferiority of drug-eluting stent with a bioabsorbable polymer

November 10, 2011

News Conference News

RAPID GENE: Validation of Point-of-Care Genetic Testing

November 09, 2011

News Conference News

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

November 09, 2011

News Industry News

OrbusNeich Introduces the Combo™ Dual Therapy Stent at TCT 2011

November 09, 2011

News Conference News

Preclinical Results Promising for Combo Stent

November 08, 2011

News Conference News

Low Event Rates with EES Sustained at 2 Years

November 08, 2011

News Conference News

EES Compared Favorably with SES In Two Pivotal Trials

November 08, 2011

News Conference News

Bioabsorbable Polymers, Scaffolds Offer Permanent Advantages

November 08, 2011

News Conference News

APICE-OCT: EES, ZES Yield Low Rates of Uncovered Struts in ACS

November 08, 2011

News Conference News

ZES, EES Noninferior to PES

November 07, 2011

News Conference News

Early Discontinuation of DAPT May Increase Risk of Stent Thrombosis

November 06, 2011

News Conference News

DES Noninferior for Survival Compared with BMS in STEMI

November 06, 2011

Advertisement

Outcomes Following Unprotected Left Main Stenting with Everolimus-Eluting Stents: the Milan Experience.

Everolimus-eluting stents show no stent thrombosis with similar one year outcomes compared with 1st and 2nd generation drug-eluting stents for the treatment of ST-segment...

Comparison by Optical Frequency-Domain Imaging of Paclitaxel-Eluting Stents and Everolimus-Eluting Stents Implanted in One Coronary Artery in One Procedure. A 12 Months Follow...

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

Paclitaxel-coated balloon angioplasty demonstrates superior results

Head-to-head comparison of two second generation drug-eluting coronary stents demonstrates non-inferiority

EVOLVE: Bioabsorbable EES Noninferior to Permanent Polymer Version

Clinical trial establishes non-inferiority of drug-eluting stent with a bioabsorbable polymer

RAPID GENE: Validation of Point-of-Care Genetic Testing

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

OrbusNeich Introduces the Combo™ Dual Therapy Stent at TCT 2011

Preclinical Results Promising for Combo Stent

Low Event Rates with EES Sustained at 2 Years

EES Compared Favorably with SES In Two Pivotal Trials

Bioabsorbable Polymers, Scaffolds Offer Permanent Advantages

APICE-OCT: EES, ZES Yield Low Rates of Uncovered Struts in ACS

ZES, EES Noninferior to PES

Early Discontinuation of DAPT May Increase Risk of Stent Thrombosis

DES Noninferior for Survival Compared with BMS in STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content